Belite Bio, Inc (BLTE) Stock: Price, Forecast & Analyst Target
Belite Bio, Inc (BLTE) — MoonshotScore 69/100 (Strong band), calculated Oct 6, 2026. Price $159.46 (-0.06%), as of the Oct 5, 2026 trading session; market cap $6.39B. Expected results Nov 9, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Belite Bio, Inc · BLTE · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Belite Bio is a clinical-stage drug developer pursuing oral therapies for retinal disease, led by a candidate designed to limit the buildup of damaging vitamin A metabolites in ocular tissue. It does not yet sell a product, so rising research expense and widening losses describe development intensity rather than customer demand. Clinical validation must ultimately convert that spending into a commercial medicine for the forecast revenue path to become credible.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Belite Bio (BLTE)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.
- EPS beat 4 of 8
- ROE -26.7% · ROA -11.6% · current ratio 50.02 · earnings yield -1.5% · free-cash-flow yield -0.0%
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 71 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 71 | Strong | |
| 71 | Strong | |
| 69 | Strong |
The score was 69 in the stored Oct 5, 2026 snapshot and remains 69 in the current publication computed Oct 6, 2026 (0); the largest pillar moves were Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $159.46 |
| Change on the day | -0.06% |
| 52-week range | $75.95–$200.00 |
| Market capitalisation | $6.39B |
| Shares traded on the day | 85.0K |
| Beta (volatility vs the S&P 500) | -1.24 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Belite Bio (BLTE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the BLTE film — every key number, told as a short cinematic story
~2 min · open the film
What is Belite Bio (BLTE), and what does it report?
Short answer · as of
Belite Bio’s main program targets Stargardt disease and atrophic age-related macular degeneration through an investigational oral therapy that modulates vitamin A delivery to the eye.
Research dated 2026-09-13.
Belite Bio’s main program targets Stargardt disease and atrophic age-related macular degeneration through an investigational oral therapy that modulates vitamin A delivery to the eye. A separate preclinical oral program extends the platform toward liver and metabolic disorders.
Reported revenue remains absent. The income statement therefore measures research progress indirectly through development expense, administrative cost and net loss, while the compact workforce reinforces the profile of a focused drug developer rather than a commercial pharmaceutical operation.
What do the latest results show for Belite Bio (BLTE)?
Short answer · as of
Against analyst estimates the company has EPS beat 4 of 8 reports.
Research dated 2026-09-13.
The latest results extend a clear pattern: research expense increased, the operating loss widened and the net loss deepened, while administrative expense eased slightly from the preceding period. Recent earnings have nevertheless been less negative than consensus expected, showing better expense outcomes relative to forecasts without changing the precommercial status of the business.
With the retinal candidate in late-stage trials, research spending is the most direct reported link between pipeline advancement and the worsening operating result. The figures support an expense-driven change, not a revenue-driven deterioration, because commercial sales remain absent.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $18.21M Jun 30, 2026
- Latest quarter · SG&A
- $16.69M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$34.91M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | $18.21M | $16.69M | −$34.91M |
| Mar 31, 2026 | Not available | $15.66M | $17.02M | −$32.68M |
| Dec 31, 2025 | Not available | $14.63M | $13.45M | −$28.08M |
| Sep 30, 2025 | Not available | $10.31M | $12.71M | −$23.02M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Above estimate Aug 12, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 12, 2026 | Not available | Not available | −$0.7000 | −$0.7300 |
| May 20, 2026 | Not available | Not available | −$0.3400 | −$0.6000 |
| Mar 2, 2026 | Not available | $16.67M | −$0.3800 | −$0.5600 |
| Nov 10, 2025 | Not available | Not available | −$0.6500 | −$0.5300 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
What are the financial strengths and risks for Belite Bio (BLTE)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$10,000 for the quarter ended Dec 31, 2025, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Reported debt is absent, liquidity ratios are exceptionally high and the distress screen appears strong. Yet the latest cash and investment balances are nil after earlier observations showed substantial liquidity, while the calculated cash decline spans the full reported window. That uneven balance-sheet picture does not support a dependable runway conclusion on its own.
An isolated operating cash-flow observation appears close to neutral, but recurring net losses and accelerating research expense show that Belite Bio is not economically self-funding. Institutional participation increased modestly, while recent insider activity consisted entirely of sales rather than purchases; neither observation explains the clinical outlook, but each matters if external capital becomes important.
Data-derived red flags
- Negative return on equity (-26.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$10,000 Dec 31, 2025
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Dec 31, 2025 | −$10,000 | $0.00 |
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Belite Bio (BLTE)?
Short answer · as of
The next earnings report is expected on Nov 9, 2026. The number it tests is the $-3.18 EPS analysts carry for it.
Research dated 2026-09-13.
The scheduled earnings update should be read for research spending, administrative discipline and whether the reported cash balance becomes consistent with the earlier liquidity history. A smaller loss relative to expectations would matter less than evidence that late-stage work is advancing without another sharp increase in the expense base.
Longer-range forecasts assume a transition from absent revenue and negative earnings to meaningful sales and profitability, but the wide forecast range signals substantial disagreement about commercialization. Progress in the retinal program is therefore the observation that must connect current spending with those estimates.
What the records here don't tell us
- No quarterly income statement is held for BLTE.
Checked against the records this page reads, on the dates shown above.
How does Belite Bio compare with its peers?
Short answer
Belite Bio's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Belite Bio differs from a diversified commercial biotechnology company because its value is concentrated in clinical validation rather than a portfolio of marketed products. Its defining feature is an oral approach to retinal disease that aims to control vitamin A metabolite accumulation, paired with an earlier program applying related biology to liver and metabolic conditions.
The compact workforce and absent revenue place the company among focused precommercial developers, but the analyst forecast spread shows unusually divergent commercialization assumptions. That makes comparison through current sales multiples less informative than comparing clinical progress, spending intensity and the durability of funding.
| Company | Price | Market value | Score |
|---|---|---|---|
| $334.85 Oct 5, 2026 | $9.87B | 98 5-pillar Oct 6, 2026 | |
| $306.77 Oct 5, 2026 | $6.15B | 96 5-pillar Oct 6, 2026 | |
| $10.11 Oct 5, 2026 | $2.34B | 94 5-pillar Oct 6, 2026 | |
| $30.39 Oct 5, 2026 | $8.54B | 90 5-pillar Oct 6, 2026 | |
| $25.15 Oct 5, 2026 | $3.15B | 88 5-pillar Oct 6, 2026 | |
| $20.11 Oct 5, 2026 | $3.44B | 76 5-pillar Oct 6, 2026 | |
| $140.63 Oct 5, 2026 | $9.08B | 76 5-pillar Oct 6, 2026 | |
| Belite Bio (BLTE) — this page | $159.46 | $6.39B | 69 |
| $84.38 Oct 5, 2026 | $5.09B | 68 5-pillar Oct 6, 2026 | |
| $40.30 Oct 5, 2026 | $4.34B | 66 5-pillar Oct 6, 2026 | |
| $53.91 Oct 5, 2026 | $8.18B | 65 5-pillar Oct 6, 2026 | |
| $42.76 Oct 5, 2026 | $7.17B | 64 5-pillar Oct 6, 2026 | |
| $118.87 Oct 5, 2026 | $4.97B | 64 5-pillar Oct 6, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $206.00 – $303.00
- Consensus target
- $245.83
- Median target
- $239.50
- Revenue estimate
- $22.50M
- EPS estimate
- $-3.18
Consensus record · Captured .
Measured against a quoted price of $159.46 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026
- Transactions
- 100
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 100
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 23.6% Period end Jun 30, 2026
- Previous quarter · ownership
- 22.9% Prior to period end Jun 30, 2026
- Reporting holders
- 82 Period end Jun 30, 2026
- Previous quarter · holders
- 75 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Darwin Global Management, Ltd. | 3,077,219 |
| Paradigm Biocapital Advisors LP | 1,232,877 |
| Rtw Investments, LP | 715,332 |
| Millennium Management LLC | 494,564 |
| Maverick Capital Ltd | 396,311 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Belite Bio (BLTE)?
What Investors Ask About Belite Bio (BLTE) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is Belite Bio trying to change in Stargardt disease?
Its oral retinal candidate is designed to modulate vitamin A delivery and prevent harmful metabolites from accumulating in ocular tissue. Clinical validation carries unusual weight because the company has no commercial revenue while research expense continues to rise.
Why can Belite Bio beat earnings expectations while remaining precommercial?
An earnings beat can result from a loss that is less negative than analysts expected, without any product sales. Recent results cleared consensus expectations while the income statement continued to show absent revenue and substantial development expense.
Does Belite Bio’s reported liquidity establish a dependable trial runway?
The liquidity picture is internally uneven: leverage is absent and liquidity ratios are strong, but the latest cash records are nil after earlier substantial balances. The calculated decline therefore deserves attention alongside future cash disclosures and the rising loss rate.
How does Belite Bio’s liver program fit beside its retinal program?
The earlier-stage oral program targets retinol-binding biology across liver and metabolic disorders, adding scientific breadth beside the late-stage retinal candidate. Financially, the company still reports as a precommercial developer, so that breadth has not produced a separate revenue stream.
What is the BLTE stock price today?
The last price recorded on this page for Belite Bio, Inc (BLTE) is $159.46, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BLTE price target?
The analyst consensus price target for Belite Bio, Inc (BLTE) is $245.83 (range $206.00 to $303.00, median $239.50), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (61 figures)
The 61 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | SAN Diego, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "12750 High Bluff Drive, San Diego, CA, 92130, US". |
FMP — 52 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $159.46 | FMP | Financial Modeling Prep (FMP) quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. | |
px.change | Change on the day | -0.06% | FMP | Financial Modeling Prep (FMP) quote | |
px.mcap | Market capitalization | $6.39B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-05. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 9, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.change_abs | Change on the day, in dollars | −$0.1036 | FMP | Financial Modeling Prep (FMP) quote | |
px.range52 | 52-week range | $75.95–$200.00 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 85.0K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | -1.24 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Yu-Hsin Lin | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 41 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $0.00, net result −$9.67M; FY2022 revenue $0.00, net result −$12.65M; FY2023 revenue $0.00, net result −$31.63M; FY2024 revenue $0.00, net result −$36.14M; FY2025 revenue $0.00, net result −$77.61M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $18.21M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $16.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$34.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $15.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $17.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$32.68M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $14.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $13.45M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$28.08M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $10.31M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $12.71M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$23.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-12.eps_actual | EPS · reported — report date 2026-08-12 | −$0.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-12.eps_estimated | EPS · estimate — report date 2026-08-12 | −$0.7300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-20.eps_actual | EPS · reported — report date 2026-05-20 | −$0.3400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-20.eps_estimated | EPS · estimate — report date 2026-05-20 | −$0.6000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-02.revenue_estimated | Revenue · estimate — report date 2026-03-02 | $16.67M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-02.eps_actual | EPS · reported — report date 2026-03-02 | −$0.3800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-02.eps_estimated | EPS · estimate — report date 2026-03-02 | −$0.5600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.eps_actual | EPS · reported — report date 2025-11-10 | −$0.6500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.eps_estimated | EPS · estimate — report date 2025-11-10 | −$0.5300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$10,000 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2025-12-31. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 8.25× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$10,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $206.00 – $303.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $245.83 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $239.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 100 transactions · 0 purchases, 100 sales, 0 other transactions · 4 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 23.6% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 22.9% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 82 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 75 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Darwin Global Management, Ltd. — shares in provider snapshot | 3,077,219 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Paradigm Biocapital Advisors LP — shares in provider snapshot | 1,232,877 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Rtw Investments, LP — shares in provider snapshot | 715,332 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Millennium Management LLC — shares in provider snapshot | 494,564 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Maverick Capital Ltd — shares in provider snapshot | 396,311 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-10 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -26.7% · ROA -11.6% · current ratio 50.02 · earnings yield -1.5% · free-cash-flow yield -0.0% | — | UNRECORDED | Stored key metrics — Date unknown |
fin.scores | Distress and quality screens | Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-3.18 | UNRECORDED | Stored analyst estimates — Captured 2026-09-06 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $22.50M | UNRECORDED | Stored analyst estimates — Captured 2026-09-06 · Expired observation |
COMPUTED — 1 fact from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-08-12.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.7000) with the recorded estimate (−$0.7300) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 69 of 100 · Strong · pillars 52 / 98 / 55 / 12 / 82 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 69 (stored snapshot Oct 5, 2026) → 69 (current publication computed Oct 6, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-12. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-12.eps_actual.comparison,earn.history.depth.2026-08-12.eps_actual,earn.history.depth.2026-08-12.eps_estimated,earn.history.depth.2026-05-20.eps_actual,earn.history.depth.2026-05-20.eps_estimated,earn.history.depth.2026-03-02.revenue_estimated,earn.history.depth.2026-03-02.eps_actual,earn.history.depth.2026-03-02.eps_estimated,earn.history.depth.2025-11-10.eps_actual,earn.history.depth.2025-11-10.eps_estimated. - Cash-flow note. Source series as of 2025-12-31. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | BELITE BIO, INC Our market-data provider lists the name as "Belite Bio, Inc"; the filer's own record is used here. | 2026-09-13 | OFFICIAL | SEC EDGAR filer record |
| Business description | Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Employees | Count: 41 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-12 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $0; Liquidity basis: cash and short-term investments; Total liabilities: $14.95M; Cash and short-term investments: $0; Cash and investments: $0; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $0; Cash and short-term investments: $0; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $0; Decline: $109.00M; Opening balance: $109.00M; Average change per period: $15.60M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Operating cash flow by quarter (USD millions) | Captured record · 1 entry
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Trailing twelve-month ratio set | Quick ratio: 33.56; Current ratio: 33.56; Return on assets: -12.9%; Return on equity: -15.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 279.92; Piotroski F-score: 2 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Institutional ownership (13F) | Holders: 82; Quarter: 2026-06-30; Ownership: 23.6%; Holders previous quarter: 75; Ownership previous quarter: 22.9 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Insider transactions, last 180 days | Net shares: -189,236; Window days: 180; Price low: $137.61; Price high: $198.09; Buy transactions: 0; Distinct insiders: 4; Sell transactions: 60; Other transactions: 0; Total transactions: 60; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-08 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Next earnings report | Date: 2026-11-09; EPS estimate: -$0.78627 per share The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.